Immune Checkpoint Inhibitors Induced Autoimmune Haemolytic Anemia: Case Series and Literature Review

Yuanqiang Wu  
Second Xiangya Hospital  

Shengchi Chen  
Nanjing First Hospital  

Jisheng Li  
Qilu Hospital of Shandong University  

Yue Pan  
Second Xiangya Hospital  

Chunhong Hu  
Second Xiangya Hospital  

Long Shu  
Second Xiangya Hospital  

Tao Hou  
Second Xiangya Hospital  

Fang Wu  (wufang4461@csu.edu.cn)  
Second Xiangya Hospital  

Research Article

Keywords: immune checkpoint inhibitors, anti-PD-1 antibody, immune-related adverse events, autoimmune haemolytic anemia, glucocorticoids.

DOI: https://doi.org/10.21203/rs.3.rs-693588/v1

License: © This work is licensed under a Creative Commons Attribution 4.0 International License.  Read Full License
Immune checkpoint inhibitors (ICIs) have brought a revolution to the anti-cancer treatment, however, they also trigger a unique spectrum of immune-related adverse events (irAEs). Among irAEs, haemopoietic AEs are rarely reported and mostly severe or even life-threatening, especially autoimmune haemolytic anaemia (AIHA). AIHA is presumed to relate to the abnormal formation of circulating autoantibodies against red cell membrane antigens. It usually cannot be discovered timely because of atypical symptoms. It is diagnosed according to presence of haemolysis evidences such as decrease of haemoglobin, increase of indirect bilirubin and lactate dehydrogenase (LDH), urobilinogen, and positive direct antiglobulin test (DAT). Treatments of AIHA are according to clinical experience and consensus, which have not been verified by prospective trial. Here we investigate previous reported ICIs induced AIHA cases including thirty detailedly documented patients. On the other hand, we report three patients who developed AIHA after three different anti-PD-1 antibodies. Most of them were aged patients with melanoma or NSCLC, developed AIHA by anti-PD-1 antibodies and relived with glucocorticoid. 43.3% of previous cases and all of our observed cases had anemia before ICIs treatment, which reminds us of anemia as a risk factor for ICIs induced AIHA. By screening parameters like complete blood examination, reticulocyte, liver function test or DAT test prior to immunotherapy, doctors could exclude pretreatment haemolytic anaemia or be aware of post ICIs AIHA. Thus, it is possible to avoid the potentially life-threatening AIHA, or improve the level of pre-alarm and treatment ability of AIHA.

Introduction

In recent decades, the anti-tumor immunotherapy has been rapidly discovered and widely developed due to its favourable anti-tumor effect and well tolerance. Undoubtedly, immune checkpoint inhibitors (ICIs) have revolutionized the treatment of cancer mainly by reactivating T cells and upregulating T cell anti-tumor responses. (Zhuang et al., 2020) Among ICIs, anti-programmed cell death 1 (PD-1) and anti-programmed death ligand 1 (PD-L1) antibodies attract most attention due to their satisfactory anti-cancer effect. Although ICIs have passed the safety evaluation and act safer than traditional chemotherapy, they can inevitably trigger a unique spectrum of immune-related adverse events (irAEs). (Kennedy and Salama, 2020) which mainly include the lung, endocrine glands, gastrointestinal system, immune system, and skin, etc. (Zhuang et al., 2020) The haemopoietic system barely gets involved. (Davis et al., 2019) ICIs mediated hematological adverse effects are as rare as 3.69% (35 out of 948 patients) in a descriptive observational study (Delanoy et al., 2019) The incidence of anemia was 9.8% for all-grade and 5% for grade 3 to grade 5 in a meta-analysis included forty-seven studies of PD-(L)1 inhibitors of 9324 evaluable patients. (Petrelli et al., 2018) In a clinical trial, the incidence of all-grade anemia was 3.84% and grade 3 or higher anemia was 0.78% for patients treated with a single-agent PD-1 or PD-L1 inhibitor. (Wang et al., 2019) Autoimmune haemolytic anaemia (AIHA) is an uncommon type of anemia and ICIs induced AIHA in extraordinary rare. ICIs induced AIHA is one of the most severe and progressive or even life-threatening irAEs with fatality as high as 15% (Davis et al., 2019) which requires extra awareness and appropriate treatment. AIHA induced by anti-PD-1 or PD-L1 antibody is exceptionally rare as reported frequency of 0.95% (9 in 948 patients) in Delanoy's observational study. (Delanoy et al., 2019) It results from red blood cell (RBC) destruction due to an abnormal activation of the immune system, (Jaime-Perez et al., 2013) of which the mechanism remains unconfirmed. It is likely relates to the formation of circulating autoantibodies against RBC membrane antigens, activation of T-cell clones, and suppression of regulatory T cells. Patients who previously accepted ICIs treatment and subsequently developed AIHA may have few atypical symptoms, such as anemic appearance, dizziness, fatigue and dark brown urine. The laboratory tests can show hemolysis related evidences such as a decrease of haemoglobin, an increase of serum indirect bilirubin and lactate dehydrogenase (LDH), urobilinogen, reticulocytosis, low serum haptoglobin and spherocytosis. (Leaf et al., 2019) Diagnosis is based on the direct antiglobulin test (DAT, Coombs test), which is usually positive for anti-immunoglobulin G and/or anti-C3d antisera. (Leaf et al., 2019) Recommendations for treating ICIs induced AIHA come from treatment of primary AIHA, (Jaime-Perez et al., 2013; Zanella and Barcellini, 2014) clinical experiences (Leaf et al., 2019; Tanios et al., 2019) and consensus (Brahmer et al., 2018; Haenan et al., 2018; Thompson et al., 2019) because no prospective trial has been conducted. (Davis et al., 2019) The information shortage of ICIs induced AIHA is because of its uncommon nature or doctors’ poor recognition. As such, reporting more cases and retrospectively summarizing previous cases are helpful for enriching the understanding on ICIs induced AIHA.

Case Analysis

Documentally reported ICIs induced AIHA is rare, including 68 cases from the World Health Organization's pharmacovigilance database of individual-case-safety reports of adverse drug reactions, VigiBase (Davis et al., 2019) 68 cases from the database of the Food and Drug Administration, (Tanios et al., 2019) and 29 cases from other previous sporadic reports. But only 30 of them were detailedly documented for us to characterize (Table 1, Table 2). Among these 30 cases, 56.7% were men aged from 18 to 85 years old and 43.3% were women aged from 33 to 85 years old. The average age is 65.1 years old, including 65.2 years old for female patients while 64.9 years old for male patients, which indicates a possible prevalence of AIHA in aged patients. The tumor types in order of prevalence were melanoma (56.7%), non-small-cell lung cancer (NSCLC, 30.0%), and other malignancies, which is consistent with the cancer prevalence in Tanios's analysis. (Tanios et al., 2019) 90.0% of the patients’ AIHA were caused by anti-PD-1 antibodies, including 40.0% by pembrolizumab, 33.3% by nivolumab, and 16.7% by nivolumab together with ipilimumab. It matches the previous discovery that anti-PD-1 antibodies cause more AEs than anti-PD-L1 antibodies or anti-CTLA-4 antibodies. (Davis et al., 2019) According to the decreasing severity of hemoglobin, all patients’ AIHA were equal to or worse than grade 2, except that 2 patients’ hemoglobin level was not mentioned. 63.3% patients (19 out of 30) gained AIHA within less than 5 cycles of ICIs. The cycle from starting the ICIs until developing AIHA varied between 1 and 39 cycles with and a median of 4 cycles, which is later than 50 days from the data analysis in VigiBase (Davis et al., 2019) and 10 weeks from the cases in Food and Drug Administration database. (Tanios et al., 2019) Except for some cases are not reported, most patients (63.3%) showed positive direct antiglobulin test either mediated by IgG or C3 or their combination. As guidelines suggested, (Brahmer et al., 2018; Haenan et al., 2018; Hill et al., 2017) all patients were treated with glucocorticoids including dexamethasone, prednisone, and methylprednisolone. For patients who did not respond satisfactorily to glucocorticoids, intravenous immunoglobulin (IVIG), anti-CD20 antibody rituximab, and immunosuppressive drug azathioprine, were administered by 10.0%, 13.3%, and 3.3%
respectively. With these treatments, 28/30 patients completely recovered from AIHA while 2/30 expired. Although 76.7% patients suffered grade 3 or higher AIHA, one third of patients re-challenged ICIs with well tolerance.

Table 1. Cases with ICIs induced AIHA detailedly reported in the literature.

Abbreviations: ys: years; ICIs, immune checkpoint inhibitors; AIHA, autoimmune haemolytic anemia; LDH: lactate dehydrogenase; Ret%: percentage of reticulocyte; DAT, direct antiglobulin test; Ref.: reference; F: female; M: male; NSCLC: non-small cell lung cancer; CRC: colorectal cancer; SCC, squamous cell carcinoma; AML: acute myelocytic leukemia; ChOL, cholangiocarcinoma; Pembro: pembrolizumab; Nivo: nivolumab; Ipi: ipilimumab; NR: not reported; GCs: glucocorticoids; Pred: prednisone; MP: methylprednisolone; Dex, dexamethasone; IVIG: intravenous immunoglobulin.

Table 2. Characteristics of patients with ICIs induced AIHA detailedly reported in the literature.
| Age/ys | Gender | Diagnosis       | ICIs       | LDH/U/L | Hemoglobin /g/dL | Ret% Baseline | Nadir | Δ | DAT Mediator | Treatment   | Outcome  | ICIs Re-challeng |
|--------|--------|-----------------|------------|---------|------------------|---------------|-------|---|--------------|-------------|----------|------------------|
| 52     | F      | Melanoma        | Pembro×3   | 1266    | 12.5             | 6.3           | 6.2   | 0.1 | IgG          | GSs, IVIG   | Recover  | No               |
| 55     | M      | Melanoma        | Pembro×1   | 399     | 10.4             | 6.3           | 4.1   | 0.3 | IgG, C3      | Pred        | Recover  | Pembro           |
| 67     | M      | Melanoma        | Pembro×8   | NR      | 15.4             | 6.6           | 8.8   | NR  | NR           | MP          | Recover  | No               |
| 68     | M      | Melanoma        | Pembro×12  | 530     | 13.6             | 8.5           | 5.1   | 4.7 | IgG          | Pred        | Recover  | Nivo             |
| 79     | F      | Melanoma        | Pembro×1   | 235     | -                | 5.0           | -     | -   | IgG, C3      | GCs         | Recover  | No               |
| 81     | F      | Melanoma        | Pembro×2ys | 1176    | 9.1              | 3.9           | 5.2   | 8.9 | IgG, C3      | MP, Pred    | Recover  | No               |
| 85     | M      | Melanoma        | Pembro×2   | 885     | 12.8             | 8.2           | 4.6   | 3.3 | Negative     | Pred, Rituximab | Recover  | No               |
| 85     | F      | Melanoma        | Pembro×10  | 1151    | 12.9             | 6.4           | 6.5   | 6.4 | IgG          | Pred, IVIG, azathioprine | Recover  | No               |
| 71     | F      | NSCLC           | Pembro×4   | 623     | 10.1             | 5.5           | 4.6   | 0.3 | Negative     | Dex         | Recover  | Pembro           |
| 73     | M      | NSCLC           | Pembro×13  | 1615    | 11.0             | 7.4           | 3.6   | NR  | NR           | Pred        | Recover  | No               |
| 78     | M      | NSCLC           | Pembro×1   | 492     | 11.7             | 6.0           | 5.7   | 7.8 | NR           | Pred        | Recover  | NR               |
| 69     | F      | CRC             | Pembro×1   | 716     | 11.7             | 9.4           | 2.3   | 4.3 | NR           | Pred        | Recover  | No               |
| 52     | M      | NSCLC           | Nivo×24    | 383     | 13.4             | 5.9           | 7.5   | 18.9| IgG          | MP          | Expired  | No               |
| 59     | F      | NSCLC           | Nivo×12    | 505     | 11.9             | 6              | 5.9   | 16.8| IgG, C3      | Pred, IVIG, Rituximab | Recover  | No               |
| 63     | F      | NSCLC           | Nivo×4     | 976     | 11.7             | 4              | 7.7   | 14.8| IgG          | MP, Pred    | Recover  | No               |
| 60     | M      | NSCLC           | Nivo×21    | 335     | 8.9              | 4.3           | -     | 17  | IgG          | MP, Pred    | Recover  | Nivo             |
| 70     | M      | NSCLC           | Nivo×2     | 330     | 10.5             | 5.5           | 5.0   | NR  | C3           | Pred        | Expired  | No               |
| 78     | M      | NSCLC           | Nivo×39    | 648     | 11–13            | 8.6           | -     | 17.0| IgG          | Pred, rituximab | Recover  | No               |
| 75     | F      | Hodgkin’s lymphoma | Nivo×2   | 409     | 12.3             | 6.4           | 5.9   | NR  | IgG          | Pred        | Recover  | Nivo             |
| 82     | M      | Cutaneous SCC   | Nivo×8     | NR      | NR               | NR            | -     | NR  | IgG, C3      | Pred        | Recover  | NR               |
| 85     | M      | Melanoma        | Nivo×5     | 682     | 6.4              | 6.4           | 7.9   |    | IgG          | Pred        | Recover  | No               |
| 33     | F      | AML             | Nivo×1     | 791     | 9.3              | 7.2           | 2.1   | 4.9 | Negative     | MP, Pred    | Recover  | No               |
| 47 | M | Melanoma | Ipi×1 | 522 | 9.5 | 6.2 | 3.3 | 3.2 | NR | Dex | Recover | Ipi |
| 68 | F | Melanoma | Ipi×3 | 580 | NR | 6.0 | - | 0.2 | NR | MP | Recover | NR |
| 71 | M | Melanoma | Ipi×4 | NR | NR | NR | - | NR | IgG, C3 | Pred | Recover | NR |
| 18 | M | Melanoma | Ipi+Nivo×4 | 784 | 12.4 | 6.2 | 6.2 | <0.5 | Negative | MP, Pred | Recover | Ipi+Nivo |
| 43 | F | Melanoma | (Ipi+Nivo)×2 | 1406 | 5.6 | 6.5 | IgG, C3 | MP, Rituximab | Recover | Ipi+Nivo |
| 48 | M | Melanoma | (Ipi+Nivo)×3 | 770 | 7.2 | 3.5 | 3.7 | 11.1 | IgG, C3 | MP, Pred | Recover | No |
| 67 | F | Melanoma | (Ipi+Nivo)×4 | 426 | 13.2 | 8.7 | 4.5 | 8.8 | IgG | Pred | Recover | Nivo |
| 67 | M | Melanoma | (Ipi+Nivo)×2 | 1574 | 13.7 | 6.2 | 7.5 | 8.5 | Negative | Dex, Pred | Recover | Ipi+Nivo |
| Characteristics                              | ICI-induced AIHA (n=30) |
|---------------------------------------------|------------------------|
| **Sex, n (%)**                              |                        |
| Female                                      | 13 (43.3)              |
| Male                                        | 17 (56.7)              |
| **Age in years, average (range)**           |                        |
| Female                                      | 65.2 (33-85)           |
| Male                                        | 64.9 (18-85)           |
| **Cancer type, n (%)**                      |                        |
| Melanoma                                    | 17 (56.7)              |
| NSCLC                                       | 9 (30)                 |
| Lymphoma                                    | 1 (3.3)                |
| Colorectal cancer                           | 1 (3.3)                |
| Cutaneous squamous cell carcinoma           | 1 (3.3)                |
| Acute myelocytic leukemia                   | 1 (3.3)                |
| **Immunotherapy agent(s), n (%)**           |                        |
| Pembrolizumab                               | 12 (40)                |
| Nivolumab                                   | 10 (33.3)              |
| Ipilimumab                                  | 3 (10)                 |
| Ipilimumab + Nivolumab                      | 5 (16.7)               |
| **ICI cycles before onset**                 |                        |
| Median (range)                              | 4 (1-39)               |
| Average (range)                             | 7.7 (1-39)             |
| **AIHA Grade**                              |                        |
| Grade 1                                     | 0                      |
| Grade 2                                     | 5 (16.7)               |
| Grade 3                                     | 14 (46.7)              |
| Grade 4                                     | 9 (30.0)               |
| Not reported                                | 2 (6.7)                |
| **DAT Mediator, n (%)**                     |                        |
| IgG                                         | 10 (33.3)              |
| C3                                          | 1 (3.3)                |
| IgG, C3                                     | 8 (26.7)               |
| NR                                          | 6 (20)                 |
| Negative                                    | 5 (16.7)               |
| **Treatment, n (%)**                        |                        |
| GSs (dexamethasone, prednisone, methylprednisolone) | 30 (100) |
| Intravenous immunoglobulin                  | 3 (10)                 |
| Rituximab                                   | 4 (13.3)               |
| Azathioprine                                | 1 (3.3)                |
| **Recovery from ICI-induced AIHA, n (%)**   |                        |
| Yes                                         | 28 (93.3)              |
| No                                          | 2 (6.7)                |
| **Re-challenge with ICIs, n (%)**           |                        |
| Yes                                         | 10 (33.3)              |
A 55-year-old woman (Table 3) presented to the emergency department complaining with dizziness, nausea and haematemesis, which also happened once seven days ago. Emergency blood test showed the RBCs count of 2.87×10^{12} /L and hemoglobin level was 87 g/ L. Iron, vitamin B12, and folate deficiency were ruled out. Positron emission tomography-computed tomography (PET-CT) revealed nodules or masses with increased glucose metabolism in both lungs, bilateral hilar and mediastinal lymph nodes, sacrum, left adrenal gland and pleura. After tissue biopsy, pathological diagnosis was made as squamous cell carcinoma of lung with PD-L1 expression over 50%, while molecular diagnosis did not find any valuable mutation. Thus, pembrolizumab was administered as first line treatment. However, one day later the patient's complete blood examination showed an astonishing decrease of RBCs to 1.34×10^{12} /L and hemoglobin to 50 g/L with normal leukocyte and platelet counts. Supplement of iron and vitamin B12 was not helpful. Furthermore, hemoglobin level lowered to 45 g/L with RBCs of 1.30×10^{12} /L in three days. The absolute reticulocyte count was 0.031×10^{12}/L and percentage of reticulocytes was 3.49%. Liver function test revealed an increase in lactate dehydrogenase (LDH, 289.7 U/L), total bilirubin (27.6 umol/L) and indirect bilirubin (13.4 umol/L). Besides, the patient complained with dark brown urine and an increased urobilinogen was found in his urine, while urine and fecal occult blood test were both positive. The DAT test was positive for IgG and C3 antibodies. Additionally, a positive antinuclear antibody was detected (granular pattern) at a titer of 1:80. Anti-U1-RNP antibody, anti-Ro-52 (52kDa) antibody, anti-histone antibody were also found positive. Echocardiography showed slight pulmonary arterial hypertension with pulmonary arterial systolic pressure of 33mmHg, while bone marrow biopsy was normal and abdominal ultrasonography did not find hepatomegaly or splenomegaly. In accord with the evidences stated above, the patient was diagnosed as AIHA and immediately received intravenous 80mg/day methylprednisolone together with other supportive treatment like gastric protection. RBC transfusion was not performed because of increased risk of additional hemolysis. Luckily, he responded well with rising level of hemoglobin and RBCs. Subsequently, his intravenous steroid was gradually tapered, and replaced with oral steroid. Finally he weaned off oral steroid in a month when his hemoglobin completely recovered.

---

**Case 3: Gastric adenocarcinoma**

A 62-year-old man (Table 3) presented to the department of oncology complaining with chest distress for half a year, occasional chest pain for half a month and vomiting after eating for a week. He also felt mental infirmity, loss of appetite and troubled sleep. During this past half year, he lost two kilograms. In the past fifty years, he suffered from a skin allergy very often but allergen was unknown. Seven years ago he was diagnosed with silicosis due to five years work history in coal mine. His smoking and alcohol history were both going back almost fifty years. His physical examinations were unremarkable except for a mild anemia appearance, while no hemorrhage was found. Blood routine showed a red blood cell count of 2.87×10^{12} /L with hemoglobin level of 87 g/ L. Iron, vitamin B12, and folate deficiency were ruled out. Positron emission tomography-computed tomography (PET-CT) revealed nodules or masses with increased glucose metabolism in both lungs, bilateral hilar and mediastinal lymph nodes, sacrum, left adrenal gland and pleura. After tissue biopsy, pathological diagnosis was made as squamous cell carcinoma of lung with PD-L1 expression over 50%, while molecular diagnosis did not find any valuable mutation. Thus, pembrolizumab was administered as first line treatment. However, one day later the patient's complete blood examination showed an astonishing decrease of RBCs to 1.34×10^{12} /L and hemoglobin to 50 g/L with normal leukocyte and platelet counts. Supplement of iron and vitamin B12 was not helpful. Furthermore, hemoglobin level lowered to 45 g/L with RBCs of 1.30×10^{12} /L in three days. The absolute reticulocyte count was 0.031×10^{12}/L and percentage of reticulocytes was 3.49%. Liver function test revealed an increase in lactate dehydrogenase (LDH, 289.7 U/L), total bilirubin (27.6 umol/L) and indirect bilirubin (13.4 umol/L). Besides, the patient complained with dark brown urine and an increased urobilinogen was found in his urine, while urine and fecal occult blood test were both positive. The DAT test was positive for IgG and C3 antibodies. Additionally, a positive antinuclear antibody was detected (granular pattern) at a titer of 1:80. Anti-U1-RNP antibody, anti-Ro-52 (52kDa) antibody, anti-histone antibody were also found positive. Echocardiography showed slight pulmonary arterial hypertension with pulmonary arterial systolic pressure of 33mmHg, while bone marrow biopsy was normal and abdominal ultrasonography did not find hepatomegaly or splenomegaly. In accord with the evidences stated above, the patient was diagnosed as AIHA and immediately received intravenous 80mg/day methylprednisolone together with other supportive treatment like gastric protection. RBC transfusion was not performed because of increased risk of additional hemolysis. Luckily, he responded well with rising level of hemoglobin and RBCs. Subsequently, his intravenous steroid was gradually tapered, and replaced with oral steroid. Finally he weaned off oral steroid in a month when his hemoglobin completely recovered.

---

**Table 3.** Cases with ICIs induced AIHA in our report.

| No         | 16(53.3) |
| NR         | 4(13.3)  |

**Abbreviations:** ICIs, immune checkpoint inhibitors; AIHA, autoimmune haemolytic anemia; DAT, direct antiglobulin test; GCs: glucocorticoids.
AIHA (Leaf et al., 2019; Tanios et al., 2019) For patients suffering from above grade 2 AIHA, corticosteroid is suggested as the first-line therapy besides of Glucocorticoids are the mainstay treatment for autoimmune side effects caused by immunotherapy, (Davis et al., 2019) which also fits for ICIs related autoimmune disorder. As a result, it is possible to avoid a potentially life-threatening AE, or improve the level of pre-alarm and treatment ability of AIHA.

**Discussion**

Immunotherapy has become a popular therapy for cancer patients in recent years, among which ICIs have been successfully applied in multiple cancers, such as melanoma, Hodgkin’s lymphoma, lung cancer, gastric cancer, etc. Although ICIs demonstrated a favorable safety profile compared to traditional chemotherapy, (Davis et al., 2019; Wang et al., 2019) ICIs induced adverse events should not be ignored. (Kennedy and Salama, 2020) As a systemic therapy, ICIs get involved in the whole immune system in addition to the local immune environment of tumor. Thus, ICIs related AEs could highly spread to the whole body or even be life-threatening with fatality as high as 15%. (Davis et al., 2019) AIHA is one of the most severe ICIs induced AEs but is rarely reported. (Delanoy et al., 2019; Kennedy and Salama, 2020, Wang et al., 2019) Beside of 68 cases from the VigiBase, (Davis et al., 2019) 68 cases from the Food and Drug Administration database, (Tanios et al., 2019) and 29 cases from other sporadic reports, we report three patients who developed AIHA after being subjected to treatment of anti-PD-1 antibodies. According to detailed analysis of thirty cases (Table 1, Table 2), and observation on three practical cases (Table 3), we found that ICIs induced AIHA mostly harms the aged patients with melanoma or NSCLC. But it should be aware of the bias of higher usage rate in the melanoma and NSCLC patients. Anti-PD-1 antibodies, particularly pembrolizumab and nivolumab, induce more AIHA than anti-PD-L1 antibodies or other ICIs. It may be explained by their molecular mechanism of interrupting wider signal pathways including PD-L1 and PD-L2.

**Table 1**

| Age/ys | Gender | Diagnosis                  | ICIs     | LDH/U/L | Hemoglobin /g/dL | Ret% | DAT Mediator | Treatment | Outcome |
|--------|--------|----------------------------|----------|---------|------------------|-------|--------------|-----------|---------|
| 62     | M      | NSCLC                      | Pembrolizumab×1 | 289     | 8.7              | 5.0   | 3.7          | 3.49 IgG, C3 | MP      | Recover |
| 63     | F      | Intrahepatic CHOL          | Camrelizumab×2 | 1395    | 10.6             | 5.1   | 5.5          | -         | Negative | MP      | Recover |
| 55     | F      | Gastric adenocarcinoma     | Nivolumab×1 | 3288    | 9.7              | 8.5   | 1.2          | -         | -       | MP      | Recover |

**Abbreviations:** yrs: years; ICIs, immune checkpoint inhibitors; AIHA, autoimmune haemolytic anemia; LDH: lactate dehydrogenase; Ret%: percentage of reticulocyte; DAT, direct antiglobulin test; F: female; M: male; NSCLC: non-small cell lung cancer; CHOL, cholangiocarcinoma; MP: methylprednisolone.

**ICIs induced AIHA is not hard to diagnose with low hemoglobin and RBCs, reticulocytosis and/or anisocytosis, elevated LDH and indirect bilirubin level, positive Coomb’s test and low serum haptoglobin. (Leaf et al., 2019) Nevertheless, the diagnosis is often delayed because the patient usually does not have typical symptoms until anemia becomes severe. The most common symptoms in AIHA are similar to general anemia such as fatigue, dizziness and breathlessness. In our experience, when the first patient complained with fever and dark brown urine, his hemoglobin level has been as low as 50 g/L. Similarly, the hemoglobin level in the second case was as low as 51 g/L when symptoms of dizziness, fatigue, and soy-colored urine were discovered. In the third case, the patient pre-existing hemorrhagic anemia confounded the physician’s awareness and judgement of the type of anemia, even though she complained with fever and dark-colored urine. Glucocorticoids were not used until the fifth day after nivolumab. Fortunately her anemia was grade 2 and immediately controlled with initial 0.8mg/kg/d methylprednisolone. As ICIs are more and more widely used, ICIs induced hematologic AEs should be paid more attention in order to obtain timely treatment benefits. Mostly cases either from previous documents (Table 1, Table 2) or our observation (Table 3) showed positive DAT test. Hence, DAT test could be routinely administered for patients with anemia after ICIs treatment to early identify AIHA.

ICIs induced AIHA is not hard to diagnose with low hemoglobin and RBCs, reticulocytosis and/or anisocytosis, elevated LDH and indirect bilirubin level, positive Coomb’s test and low serum haptoglobin. (Leaf et al., 2019) Nevertheless, the diagnosis is often delayed because the patient usually does not have typical symptoms until anemia becomes severe. The most common symptoms in AIHA are similar to general anemia such as fatigue, dizziness and breathlessness. In our experience, when the first patient complained with fever and dark brown urine, his hemoglobin level has been as low as 50 g/L. Similarly, the hemoglobin level in the second case was as low as 51 g/L when symptoms of dizziness, fatigue, and soy-colored urine were discovered. In the third case, the patient pre-existing hemorrhagic anemia confounded the physician’s awareness and judgement of the type of anemia, even though she complained with fever and dark-colored urine. Glucocorticoids were not used until the fifth day after nivolumab. Fortunately her anemia was grade 2 and immediately controlled with initial 0.8mg/kg/d methylprednisolone. As ICIs are more and more widely used, ICIs induced hematologic AEs should be paid more attention in order to obtain timely treatment benefits. Mostly cases either from previous documents (Table 1, Table 2) or our observation (Table 3) showed positive DAT test. Hence, DAT test could be routinely administered for patients with anemia after ICIs treatment to early identify AIHA.

According to general clinical experience and consensus on AIHA so far, (Brahmer et al., 2018; Haanen et al., 2018; Jaime-Perez et al., 2013; Leaf et al., 2019; Tanios et al., 2019; Zanella and Barcellini, 2014) implementation of the appropriate treatment should depend on the severity of AIHA. (Brahmer et al., 2018) Glucocorticoids are the mainstay treatment for autoimmune side effects caused by immunotherapy, (Davis et al., 2019) which also fit for ICIs related AIHA. (Leaf et al., 2019; Tanios et al., 2019) For patients suffering from above grade 2 AIHA, corticosteroid is suggested as the first-line therapy beside of elimination of ICIs. (Brahmer et al., 2018) After initial remission, the dosage should be tapered down slowly with caution, while maintenance dose is frequently
required. If no sign of improvement or worsening symptoms while on corticosteroids, doctors should consider initiating conventional immunosuppressive drugs, such as IVIG, cyclosporin A, and mycophenolate mofetil. (Brahmer et al., 2018; Zanella and Barcellini, 2014) AIHA is presumed to be mediated via autoantibodies produced by B-lymphocytes and plasma cells. (Jaime-Perez et al., 2013) The intervention of drugs that are specific for the B-cell compartment may reduce the secretion of abnormal antibodies. B-cell specific blocking does not interrupt T-cell mediated anti-cancer immune function, so that to preserve the therapeutic effects of ICIs. Thus, B-cell depletion with rituximab is an alternative method for relapsed or refractory AIHA. (Reynaud et al., 2015) Otherwise, new anti-CD20 monoclonal antibody ofatumumab and anti-CD52 monoclonal antibody alemtuzumab are optional therapeutic approaches. (Zanella and Barcellini, 2014) RBCs transfusion is beneficial in increasing oxygen-carrying capacity provided by the transfused RBCs as a supportive treatment, however, it may increase the risk of further hemolysis and its application require extra cautiousness. In our second case, the patient’s anemia did not improve after RBC transfusion, instead, her hemoglobin deteriorate to 40 g/L. It is methylprednisolone that brought her hemoglobin back to normal gradually and saved her from severe anemia. Our other two cases, the same as the previously reported 28 cases shown in Table 1, responded well to glucocorticoids and recover from AIHA. Whereas two men (Palla et al., 2016; Tanios et al., 2019) were not successfully rescued by corticosteroids, instead they expired in a short time. For patients not benefitting from glucocorticoids, second-line therapy of other immune-suppressive or immuno-modulating drugs should be considered.

Recent guidelines suggest that patients with less than grade 3 AIHA should temporary discontinue ICIs and patients with equal to or worse than grade 3 AIHA should permanently discontinue ICIs. (Brahmer et al., 2018; Haanen et al., 2018; Thompson et al., 2019) Our three patients followed the guideline by not re-challenging ICIs and were administered different therapy. Nevertheless, ten (Algaze et al., 2018; Khan et al., 2017; Leaf et al., 2019; Tardy et al., 2017) out of thirty patients (Table 1) reused ICIs and did not subsequently report uncontrolled AIHA. The safety of re-challenging ICIs is uncertain based on mere experience from limited clinical cases. Further prospective trials are required to test whether or not it is worthy to take such big a risk.

Conclusion

ICIs induced AIHA requires more consciousness due to its severity and high fatality. Early recognition and prompt treatment are important in mitigating its severity and improving the recovery of AIHA. Previously reported cases and our three cases remind us that risk assessments, especially hemolysis related tests, are necessary and needed to be done prior to initiating ICIs treatment for patients previously with anemia. Because of the rarity of AIHA, guidelines for treatment, monitoring and re-challenging are all immature, which demands further prospective trials to optimize public understanding on AIHA.

Abbreviations

ICIs, immune checkpoint inhibitors; PD-1, programmed cell death 1; PD-L1, programmed death ligand-1; AE, adverse events; irAE, immune-related adverse events; AIHA, autoimmune haemolytic anemia; NSCLC: non-small cell lung cancer; CHOL, cholangiocarcinoma; RBC, red blood cell; LDH, lactate dehydrogenase; DAT, Coombs test, direct antiglobulin test; PET-CT, Positron Emission Tomography-Computed Tomography; CT, computed tomography; MRI, magnetic resonance imaging; IVIG: intravenous immunoglobulin.

Declarations

Acknowledgments

We sincerely thank colleagues in Department of Oncology, Respiratory and Rheumatology in the Second Xiangya Hospital, Central South University for their cooperation in distinguishing AIHA.

Funding

This work was supported by CSCO-BMS Oncologic Research Foundation (Grant No. Y-BMS2019-100), Guangdong Provincial Key Lab of Translational Medicine in Lung Cancer (Grant No. 2017B030314120) and Guangdong Association of Clinical Trials (GACT), Changsha Science and Technology Plan Project (Grant No. kq1907077).

Conflict of interest statement

The authors declare that there is no conflict of interest.

Consent

Written informed consent was obtained from the patients or their legally authorized representative for publication of patient related clinical data.

References

1. Algaze SD, Park W, Harrington TJ, Mudad R (2018) Autoimmune haemolytic anaemia in a patient with advanced lung adenocarcinoma and chronic lymphocytic leukaemia receiving nivolumab and intravenous immunoglobulin. BMJ Case Rep 2018. http://dx.doi.org/10.1136/bcr-2017-221801
2. Brahmer JR, Lacchetti C, Schneider BJ, Atkins MB, Brassil KJ, Caterino JM, Chau I, Ernstoff MS, Gardner JM, Ginex P et al (2018) Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 36:1714–1768. http://dx.doi.org/10.1200/JCO.2017.77.6385
3. Bu X, Zhang T, Wang C, Ren T, Wen Z (2015) IL-33 reflects dynamics of disease activity in patients with autoimmune hemolytic anemia by regulating autoantibody production. J Transl Med 13:381. http://dx.doi.org/10.1186/s12967-015-0745-0
4. Davis EJ, Salem JE, Young A, Green JR, Ferrell PB, Ancell KK, Lebrun-Vignes B, Moslehi JJ, Johnson DB (2019) Hematologic Complications of Immune Checkpoint Inhibitors. Oncologist. 24, 584–588. http://dx.doi.org/10.1634/theoncologist.2018-0574

5. Delano N, Michot JM, Comont T, Kramkimel N, Lazarovic J, Dupont R, Champaib S, Chahine C, Robert C, Herbaux C et al (2019) Haematological immune-related adverse events induced by anti-PD-1 or anti-PD-L1 immunotherapy: a descriptive observational study. Lancet Haematol 6, e48–e57. http://dx.doi.org/10.1016/S2352-3026(18)30175-3

6. Haanen J, Carbonnel F, Robert C, Kerr KM, Peters S, Larkin J, Jordan K, Committee EG (2018) Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 29:iv264–iv266. http://dx.doi.org/10.1093/annonc/mdy162

7. Hill QA, Stamps R, Massey E, Grainger JD, Provan D, Hill A, Society B for Haematology G (2017) Guidelines on the management of drug-induced immune and secondary autoimmune, haemolytic anaemia. Br J Haematol 177, 208–220. http://dx.doi.org/10.1111/bjh.14654

8. Jaime-Perez JC, Rodriguez-Martinez M, Gomez-de-Leon A, Tarin-Arzaga L, Gomez-Almaguer D (2013) Current approaches for the treatment of autoimmune hemolytic anemia. Arch Immunol Ther Exp (Warsz) 61:385–395. http://dx.doi.org/10.1007/s00005-013-0232-3

9. Johnstone R, Khan O (2019) Pembrolizumab-associated autoimmune haemolytic anaemia. BMJ Case Rep 12. http://dx.doi.org/10.1136/bcr-2018-229064

10. Kennedy LB, Salama AKS (2020) A review of cancer immunotherapy toxicity. CA Cancer J Clin. http://dx.doi.org/10.3322/caac.21596

11. Khan U, Ali F, Khurram MS, Zaka A, Hadid T (2017) Immunotherapy-associated autoimmune hemolytic anemia. J Immunother Cancer 5, 15. http://dx.doi.org/10.1186/s13045-017-0214-9

12. Kong BY, Micklethwait K, Swaminathan S, Kefferd RF, Carlino MS (2016) Autoimmune hemolytic anemia induced by anti-PD-1 therapy in metastatic melanoma. Melanoma Res 26:202–204. http://dx.doi.org/10.1097/CMR.0000000000000232

13. Leaf RK, Ferreri C, Rangachari D, Mier J, Witteles W, Anstas G, Anagnostou T, Zurbir L, Piotrowska Z, Oo TH et al (2019) Clinical and laboratory features of autoimmune hemolytic anemia associated with immune checkpoint inhibitors. Am J Hematol 94:563–574. http://dx.doi.org/10.1002/ajh.25448

14. Mqadmi A, Zheng X, Yazdanbakhsh K (2005) CD4 + CD25 + regulatory T cells control induction of autoimmune hemolytic anemia. Blood 105:3746–3748. http://dx.doi.org/10.1182/blood-2004-12-4692

15. Nair R, Gheith S, Nair SG (2016) Immunotherapy-Associated Hemolytic Anemia with Pure Red-Cell Aplasia. N Engl J Med 374:1096–1097. http://dx.doi.org/10.1056/NEJMc1509362

16. Ni D, AlZahrani F, Snylie M (2019) AIHA and Pancytopenia as Complications of Pembrolizumab Therapy for Metastatic Melanoma: A Case Report. Case Rep Oncol 12:456–465. http://dx.doi.org/10.1159/000500856

17. Ogawa K, Ito J, Fujimoto D, Morita M, Yoshizumi Y, Aiyoshi K, Tomii K, Katakami N (2018) Exacerbation of autoimmune hemolytic anemia induced by the first dose of programmed death-1 inhibitor pembrolizumab: a case report. Invest New Drugs 36:509–512. http://dx.doi.org/10.1007/s10637-018-0561-5

18. Okawa S, Kayatani H, Fujiwara K, Oseki T, Takada K, Iwamoto Y, Minami D, Sato K, Shibayama T (2019) Pembrolizumab-induced Autoimmune Hemolytic Anemia and Hemophagocytic Lymphohistiocytosis in Non-small Cell Lung Cancer. Intern Med 58:699–702. http://dx.doi.org/10.2169/internalmedicine.1001-18

19. Palla AR, Kennedy D, Mosharrafa H, Doll D (2016) Autoimmune Hemolytic Anemia as a Complication of Nivolumab Therapy. Case Rep Oncol 9:691–697. http://dx.doi.org/10.1159/000452296

20. Petrelli F, Ardito R, Bortonovo K, Lonati V, Cabiddu M, Ghilardi M, Barni S (2018) Haematological toxicities with immunotherapy in patients with cancer: a systematic review and meta-analysis. Eur J Cancer 103:7–16. http://dx.doi.org/10.1016/j.ejca.2018.07.129

21. Ramos B, Gastal G, Rovere RK An Autoimmune Haemolytic Anemia Secondary to Ipilimumab Treatment. Klin Onkol 30, 128–130. http://dx.doi.org/10.14735/amko20171228

22. Reynaud Q, Durieu I, Dutertre M, Ledochowski S, Durupt S, Michallet AS, Vital-Durand D, Lega JC (2019) Clinical and laboratory features of autoimmune hemolytic anemia: A meta-analysis of 21 studies. Autoimmun Rev 14:304–313. http://dx.doi.org/10.1016/j.autrev.2014.11.014

23. Robilliard B, Amaud E, Gastaud L, Broner J (2018) A case of pembrolizumab-induced autoimmune haemolytic anaemia with polymyalgia rheumatica. Eur J Cancer 103:281–283. http://dx.doi.org/10.1016/j.ejca.2018.07.318

24. Schwab KS, Heine A, Weimann T, Kristiansen G, Grossart P (2016) Development of Hemolytic Anemia in a Nivolumab-Treated Patient with Refractory Metastatic Squamous Cell Skin Cancer and Chronic Lymphatic Leukemia. Case Rep Oncol 9:373–378. http://dx.doi.org/10.1159/000447508

25. Shaikh H, Daboul N, Albrethsen M, Fazal S (2018) A case of autoimmune haemolytic anaemia after 39 cycles of nivolumab. BMJ Case Rep 2018. http://dx.doi.org/10.1136/bcr-2018-224608

26. Simeone E, Grimaldi AM, Esposito A, Curvietto M, Palla M, Paone M, Mozzillo N, Asciento PA (2014) Serious haematological toxicity during and after ipilimumab treatment: a case series. J Med Case Rep 8:240. http://dx.doi.org/10.1186/1752-1947-8-240

27. Tanios GE, Doley PB, Munker R (2019) Autoimmune hemolytic anemia associated with the use of immune checkpoint inhibitors for cancer: 68 cases from the Food and Drug Administration database and review. Eur J Haematol 102:157–162. http://dx.doi.org/10.1111/ehj.13187

28. Tardy MP, Gastaud L, Boscaglia A, Peyrade F, Gallamini A, Thyss A (2017) Autoimmune hemolytic anemia after nivolumab treatment in Hodgkin lymphoma responsive to immunosuppressive treatment. A case report. Hematol Oncol 35:875–877. http://dx.doi.org/10.1002/10.2338

29. Thompson JA, Schneider BJR, Frahmer J, Andrews S, Arman R, Bhatia S, Budde LE, Costa L, Davies M, Dunnington D et al (2019) Management of Immunotherapy-Related Toxicities, Version 1.2019. J Natl Compr Canc Netw 17:255–289. http://dx.doi.org/10.6004/jnccn.2019.0013

30. Wang Y, Zhou S, Yang F, Qi X, Wang X, Guan X, Shen C, Duma N, Aguileras V, Chintakuntlawar J A, et al. (2019) Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical Trials: A Systematic Review and Meta-analysis. JAMA Oncol. http://dx.doi.org/10.1001/jamaoncol.2019.0393
31. Williams H, Aitchison R (2019) Pembrolizumab-induced autoimmune haemolytic anaemia and cholangitis. BMJ Case Rep 12. http://dx.doi.org/10.1136/bcr-2019-232505

32. Xu L, Zhang T, Liu Z, Li Q, Xu Z, Ren T (2012) Critical role of Th17 cells in development of autoimmune hemolytic anemia. Exp Hematol 40:994–1004 e1004. http://dx.doi.org/10.1016/j.exphem.2012.08.008

33. Zanella A, Barcellini W (2014) Treatment of autoimmune hemolytic anemias. Haematologica 99:1547–1554. http://dx.doi.org/10.3324/haematol.2014.114561

34. Zhuang J, Du J, Guo X, Zhou J, Duan L, Qiu W, Si X, Zhang L, Li Y, Liu X et al (2020) Clinical diagnosis and treatment recommendations for immune checkpoint inhibitor-related hematological adverse events. Thorac Cancer 11:799–804. http://dx.doi.org/10.1111/1759-7714.13281